应用超微血管成像(SMI)评估浸润性导管癌患者血管生成组织学标志物的初步研究
本研究纳入54例浸润性导管癌女性患者,活检前用SMI评估瘤内及瘤周微血管参数,并与VEGF、ERG、CD34等血管生成组织学标志物进行关联分析。结果显示瘤周VEGF和ERG高表达者SMI血管指数更高,瘤周ERG高表达还与复杂血管形态、穿入血管及中央血流相关;腋窝淋巴结转移者血管指数更高、形态更复杂。作者认为基于组织学标志物的新生血管活性与SMI参数相关,需更大样本研究评估诊断准确性和风险分层效用。
要点
- 瘤周ERG高表达者SMI血管指数更高(7.2±6.3 vs 2.4±1),复杂血管形态、穿入血管、中央血流比例也更高。
- 瘤周VEGF高表达者SMI血管指数更高(7±6.4 vs 3.7±0.9,P=.003)。
- 腋窝淋巴结转移者SMI血管指数更高(10±7.6 vs 4.2±3),复杂形态及穿入血管比例更高。
核心结论
- 在该初步研究中,基于组织学标志物新生血管活性较高的肿瘤,其SMI血管指数、复杂血管形态、穿入血管及中央血流相应增加。
- 作者指出需要更大规模的研究来评估SMI的诊断准确性及患者风险分层的效用。
研究设计与样本
- 本研究为初步研究,纳入54例浸润性导管癌女性患者,平均年龄49.5±14.8岁。
- 所有患者在活检前接受SMI检查,评估Adler分级、血管指数、形态、分布及穿入等定性和定量血管参数。
- 对活检标本的瘤内和瘤周区域进行免疫组化染色分析VEGF、ERG和CD34,依据Allred评分系统半定量分为低表达和高表达组。
- 分析组织学标志物与SMI参数之间的关联,并按病灶大小、腋窝淋巴结转移及组织学分级进行亚组分析。
关键影像表现/征象
- 瘤周VEGF高表达组SMI血管指数为7±6.4(95%CI 5.2-8.8),高于低表达组的3.7±0.9(95%CI 2.3-5.2),P=.003。
- 瘤周ERG高表达组血管指数为7.2±6.3(95%CI 5.4-9.0),高于低表达组的2.4±1(95%CI 1.1-3.8),P<.001。
- 瘤周ERG高表达组复杂血管形态比例为66.7% vs 20%(P=.024),穿入血管为63% vs 20%(P=.037),中央血流为77.6% vs 20%(P=.006)。
- 瘤内ERG高表达组复杂血管形态比例为85.7% vs 60%(P=.047)。
- 腋窝淋巴结转移组血管指数为10±7.6(95%CI 6.7-13.2),高于无转移组的4.2±3(95%CI 3.1-5.3),P<.001;转移组复杂形态83.3% vs 53.3%(P=.020),穿入血管63.2% vs 50%(P=.027),瘤周ERG高表达100% vs 83.3%(P=.045)。
诊断标准与关键数值
- SMI血管参数包括Adler分级、血管指数、血管形态、分布及穿入,血管指数以均值±标准差及95%CI报告。
- 组织学标志物VEGF、ERG和CD34的表达水平依据Allred评分系统半定量分为低表达和高表达组。
临床应用与阅片要点
- 阅片时可关注SMI上的血管指数、复杂血管形态、穿入血管和中央血流,这些参数与瘤周VEGF、ERG高表达及腋窝淋巴结转移相关。
- 作者指出需更大规模研究评估SMI的诊断准确性及风险分层效用,目前尚不能据此确定临床决策阈值。
局限性
- 原文明确本研究为初步研究(pilot study),样本量为54例。
- 作者指出需要更大规模的研究来评估SMI的诊断准确性及患者风险分层的效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Increasing microvessel density and angiogenesis are linked to a poor prognosis in patients with invasive ductal carcinoma (IDC) of the breast. This study aims to investigate intratumoral and peritumoral microvascular flow using superb microvascular imaging (SMI) in patients with IDC and explore its association with histologic markers of tumoral angiogenesis.
METHODS: Fifty-four female patients with IDC (mean age 49.5 ± 14.8 years) were evaluated using SMI before biopsy. The quantitative and qualitative vascular parameters on SMI (Adler's classification, vascular index, morphology, distribution, and penetration) were assessed. Histologic markers of angiogenesis (VEGF, ERG, and CD34) were analyzed via immunohistochemical staining in both intratumoral and peritumoral compartments of biopsy specimens. The expression levels were categorized semi-quantitatively as low or high groups based on the Allred scoring system. The association between histological and SMI parameters was analyzed. Subgroup analysis was performed according to lesion size, axillary lymph node metastasis, and histological grade.
RESULTS: IDCs with higher expression of VEGF in the peritumoral region showed a higher vascular index (7 ± 6.4 [95% CI 5.2-8.8] versus 3.7 ± 0.9 [95% CI 2.3-5.2], P = .003) on SMI. Likewise, high peritumoral ERG expression was linked to a higher vascular index (7.2 ± 6.3 [95% CI 5.4-9.0] versus 2.4 ± 1 [95% CI 1.1-3.8], P < .001), complex vessel morphology (66.7% versus 20%, P = .024), penetrating vessels (63% versus 20%, P = .037), and central vascularity (77.6% versus 20%, P = .006). Tumors with higher intratumoral ERG expression demonstrated a more complex vessel morphology on SMI (85.7% versus 60%, P = .047). The presence of axillary lymph node metastasis was associated with a higher vascular index (10 ± 7.6 [95%CI 6.7-13.2] versus 4.2 ± 3 [95%CI 3.1-5.3], < .001), complex morphology (83.3% versus 53.3%, P = .020), and penetrating vessels (63.2% versus 50%, P = .027) on SMI, as well as higher peritumoral ERG expression (100% versus 83.3%, P = .045).
CONCLUSIONS: In this pilot study, tumors with higher neo-angiogenic activity based on histological markers correlate with increased vascular index, complex vessel morphology, penetrating vessels, and central vascularity on SMI. Larger studies are needed to assess the diagnostic accuracy and utility of risk stratification of patients.
引用
- Kayadibi Y, Kargin OA, Aladag Kurt S, et al. Pilot Study to Evaluate the Association Between Superb Microvascular Imaging (SMI) and Histologic Markers of Angiogenesis in Patients With Invasive Ductal Carcinoma. J Ultrasound Med. 2025. PMID: 40042161. doi:10.1002/jum.16674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。